Yanni Hao
Janssen Pharmaceutica
13 Papers
60 Citations
Yanni Hao is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Abiraterone acetate & Prostate cancer. The author has an hindex of 7, co-authored 11 publications.
Chat about Author
Papers
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
Christopher J. Logothetis,Ethan Basch,Arturo Molina,Karim Fizazi,Scott North,Kim N. Chi,Robert Jones,Oscar B. Goodman,Paul N. Mainwaring,Cora N. Sternberg,Eleni Efstathiou,Dennis D. Gagnon,Margaret Rothman,Yanni Hao,Cameron S. Liu,Thian Kheoh,C. M. Haqq,Howard I. Scher,Johann S. de Bono +18 more
TL;DR: In patients with metastatic castration-resistant prostate cancer previously treated with docetaxel, abiraterone acetate and prednisone offer significant benefits compared withprednisone alone in terms of pain relief, delayed pain progression, and prevention of skeletal-related events.
287
Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study.
Christopher J. Logothetis,J.S. de Bono,Ana M. Molina,E. M. Basch,Karim Fizazi,Scott North,Kim N. Chi,Robert Jones,Oscar B. Goodman,Paul N. Mainwaring,Cora N. Sternberg,Dennis D. Gagnon,R. Dhawan,Margaret Rothman,Yanni Hao,Cameron S. Liu,T. Kheoh,Howard I. Scher,C. M. Haqq +18 more
TL;DR: Therapy with AA + P offers significant clinical benefits, incl.
33
7001 ORAL Abiraterone Acetate Improves Functional Status in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Post-docetaxel – Results From the COU-AA-301 Phase 3 Study
S. J. Harland,J.S. de Bono,C. M. Haqq,John Staffurth,Yanni Hao,Dennis D. Gagnon,Cameron S. Liu,Cora N. Sternberg,Ana M. Molina,Howard I. Scher +9 more
11
7015 POSTER DISCUSSION Fatigue Improvement/Reduction With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel – Results From the COU-AA-301 Phase 3 Study
Cora N. Sternberg,Howard I. Scher,Ana M. Molina,Scott North,Paul N. Mainwaring,Yanni Hao,Dennis D. Gagnon,T. Kheoh,C. M. Haqq,J.S. de Bono +9 more
7
The Impact of Abiraterone Acetate (AA) Therapy on Patient-Reported Pain and Functional Status in Chemotherapy-Naive Patients with Progressive, Metastatic Castration-Resistant Prostate Cancer (MCRPC)
Ethan Basch,Charles J. Ryan,Thian Kheoh,Karim Fizazi,Christopher J. Logothetis,Dana E. Rathkopf,Matthew R. Smith,Paul N. Mainwaring,Yanni Hao,Thomas W. Griffin,Susan Li,Michael L. Meyers,Arturo Molina,Charles S. Cleeland +13 more
TL;DR: In asymptomatic/minimally symptomatic mCRPC, AA + P delayed functional decline and progression of pain compared to PL +-P alone, suggesting that AA is a suitable therapy option in this setting.
3